Health
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18
- DNA immunotherapy candidate VGX-3100 demonstrated clinically significant reduction of HPV-16/18-associated precancerous vulvar lesions in 63% of treated participants six months after treatment - Phase 2 results indicate that VGX-3100 can be a safe, tolerable and efficacious adjunct to current ...
2021-01-06 21:00
4471
RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease
TEL AVIV, Israel and RALEIGH, NC, Jan. 6, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
2021-01-06 20:24
6308
Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member
FREIBURG, Germany, Jan. 6, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, has secured up toEUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from ven...
2021-01-06 17:00
1944
Yiling Pharma expects to double its YoY net profit in 2020
SHIJIAZHUANG, China, Jan. 6, 2021 /PRNewswire/ -- Yiling Pharmaceutical, a Shenzhen stock market listed enterprise (002603.SZ), has recently published its 2020 earnings projection. The yearly net profit belonging to its shareholders is anticipated to be between 1.152 billion Chinese yuan and 1.27...
2021-01-06 16:55
7232
JOYSBIO's COVID-19 antigen test kit is capable of detecting the new SARS-COV-2 strain found in the United Kingdom and the United States
BINHAI, Tianjin, Jan. 6, 2021 /PRNewswire/ -- As the world watches a concerning new strain of SARS-COV-2 first identified in theUnited Kingdom, one global biotech company has announced that their antigen test kit can detect the variant. JOYSBIO Biotechnology Co.'s SARS-CoV-2 Antigen Rapid Test K...
2021-01-06 15:11
2722
Dr Ivan Puah Predicts 2021 To Be A Year Of Evolving Cosmetic Surgery & Lifestyle Changes In Singapore In The COVID-19 Era
SINGAPORE, Jan. 6, 2021 /PRNewswire/ -- It's been a year since COVID-19 disrupted lives and livelihoods. Prime Minister ofSingapore, Mr. Lee Hsien Loong, has recently announced that Singaporeans can expect the vaccines to be made available in early 2021. This good news brings much relief to th...
2021-01-06 14:27
2297
New Resource for Survivors from NCCN Helps Guide Life After Cancer Diagnosis and Treatment
PLYMOUTH MEETING, Pennsylvania, Jan. 5, 2021 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®) announced the publication of new, free informational resources on health and wellness for cancersurvivors. These two newNCCN Guidelines for Patients® are focused on healthy livin...
2021-01-05 21:35
1697
Connect Biopharma Establishes Scientific Advisory Board Comprised of Clinical Development and Program Indication Experts
Company's product development strategies to be enhanced by deep experience in dermatology, allergy and inflammatory diseases and successful drug approvals SAN DIEGO and TAICANG, SUZHOU, China, Jan. 5, 2021 /PRNewswire/ -- Connect Biopharma, a global clinical-stage biopharmaceutical company focuse...
2021-01-05 21:00
2411
Gift of Life Donor Program Leads U.S. in Organ Donation for 13th Consecutive Year
Region Demonstrates Extraordinary Generosity and Clinical Leadership Despite Pandemic Challenges: Most Organ Donors Every Year Since 2008 PHILADELPHIA, Jan. 5, 2021 /PRNewswire/ -- For the 13th consecutive year, Gift of Life Donor Program leads the nation in the most organ donors among all 58 U....
2021-01-05 20:43
3540
Global Cord Blood Announces NHC Policy Update
HONG KONG, Jan. 5, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today reported thatChina's National Health Commission ("NHC") ...
2021-01-05 20:30
11911
Chiauranib, an Anti-tumor Drug Developed by Chipscreen, is Given CDE "Breakthrough Therapy Designation"
SHENZHEN, China, Jan. 5, 2021 /RPNewswire/ -- Last December 25, the anti-tumor drug candidate Chiauranib, developed by Shenzhen Chipscreen Biosciences Co., Ltd., was granted with the "Breakthrough Therapy Designation Drug" by the Center for Drug Evaluation (CDE) and currently enter a phase III cl...
2021-01-05 17:49
2969
Bay Materials Obtains Patents to Protect Innovative Clear-Aligner Material Zendura™ FLX
FREMONT, California, Jan. 5, 2021 /PRNewswire/ -- Bay Materials LLC, a leader in high-performance thermoformable plastic materials for orthodontic clear aligner therapy (CAT), today announced that the U.S. Patent and Trademark office has allowed and issued its second patent for Bay's "Dual Shell ...
2021-01-05 17:15
3356
Terumo Enters 100th Anniversary Year
TOKYO, Jan. 5, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) is celebrating its 100th anniversary this year - marking 100 years of 'Contributing to Society through Healthcare' onSeptember 17, 2021. The company has established 'Stride Ahead' as a slogan, to celebrate and connect all Terumo ...
2021-01-05 15:00
11652
Y-Biologics signed License Agreement with 3D Medicines for T cell bispecific engager in Greater China territory
DAEJEON, South Korea and SHANGHAI, Jan. 5, 2021 /PRNewswire/ -- The South Korean biotech company Y-Biologics and theChina-based biopharmaceutical company 3D Medicines have entered into a License Agreement granting exclusive rights to develop, manufacture, and commercialize YBL-013, a T cell bi-sp...
2021-01-05 09:00
2645
Ascentage Pharma Announces its 9th Orphan Drug Designation from the US FDA in 2020, Setting a Record for Chinese Biopharmaceutical Companies
SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Adm...
2021-01-05 08:32
3063
Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer
SHANGHAI and HONG KONG, Jan. 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncolo...
2021-01-05 08:00
3856
AGC Biologics Confirms Cell and Gene Therapy Commercial Expertise as Manufacturer of Orchard Therapeutics' Newly Approved Libmeldy(TM)
SEATTLE, Jan. 4, 2021 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), is the first manufacturer of Orchard Therapeutics' Libmeldy™, which was recently approved by the European Commission (EC) as a one-time therapy for ...
2021-01-04 22:30
4029
Regent Pacific Announces Key Progresses On FORTACIN(TM) / SENSTEND(TM) - Solution to Premature Ejaculation
CHINA * Regent Pacific received US$0.72 million (approximately HK$5.62 million, (net of 10% PRC withholding tax) from Wanbang Pharmaceutical on29 December 2020 * The Clinical Trial Approval ("CTA") will be obtained from the Center of Drug Evaluation by the end ofQ1 2021 * Regent Pacific to ...
2021-01-04 21:30
13719
INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China
PLYMOUTH MEETING, Pa. and SUZHOU, China, Jan. 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("A...
2021-01-04 21:00
5150
Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL
SHANGHAI and HONG KONG, Jan. 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncolo...
2021-01-04 08:00
4557
Week's Top Stories
Most Reposted
Senetas and Nokia Announce Strategic Alliance to Secure Mission-Critical Networks for Defence and Government
[Picked up by 312 media titles]
2025-11-27 07:25SpeQtre, the entanglement-based quantum comms demonstrator satellite, is now on orbit
[Picked up by 294 media titles]
2025-11-29 09:00
Pop the 90s: The Westin Surabaya and Four Points Pakuwon Indah Welcomes 2026 with a Spectacular Live Show Featuring Project Pop
[Picked up by 286 media titles]
2025-11-26 10:49
Lincah Acquires Orderfaz to Strengthen Southeast Asia's Social Commerce Infrastructure
[Picked up by 283 media titles]
2025-11-26 09:00
MetaOptics Announces Strategic Share Placement to Accelerate Growth and Meet Rising Global Demand
[Picked up by 282 media titles]
2025-12-01 08:30Most Read
MINISO Unveils Australia's First and Largest MINISO LAND Flagship at Sydney Chatswood
2025-11-27 18:56
2607
